Leuxinostat
Leuxinostat is an inhibitor for HDAC with IC50 of 30 nM for hHDAC6. Leuxinostat inhibits the proliferation of cells THP1, K562, U937 and MEK1, induces apoptosis in leukemia cells NB4 and MOLT-4. Leuxinostat inhibits the expansion of hematopoietic stem cells and exhibits antileukemic activity in zebrafish models[1].
Product Specifications
UNSPSC
12352211
Target
Apoptosis; HDAC
Type
Reference compound
Related Pathways
Apoptosis; Cell Cycle/DNA Damage; Epigenetics
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/leuxinostat.html
Smiles
O=C(NO)C(C=C1)=CC=C1CN2CCN(C3=CC=C([N+]([O-])=O)C=C3)CC2
Molecular Formula
C18H20N4O4
Molecular Weight
356.38
References & Citations
[1]Carullo G, et al., Development of Epigenetic Modifiers with Therapeutic Potential in FMS-Related Tyrosine Kinase 3/Internal Tandem Duplication (FLT3/ITD) Acute Myeloid Leukemia and Other Blood Malignancies. ACS Pharmacol Transl Sci. 2024 Jul 2;7 (7) :2125-2142.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
HDAC1; HDAC10; HDAC11; HDAC3; HDAC6; HDAC8
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
BNC940031-100 1x 100 µL
Mucin 5AC (MUC5AC) (45M1), CF594 conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC400017-500 1x 500 µL
Ep-CAM / CD326 (VU-1D9), CF640R conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
